Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in psychiatric disorders and suicidal behavior

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The hypothalamic-pituitary-adrenal (HPA) axis is a feedback loop that includes the hypothalamus, the pituitary and the adrenal glands. The HPA axis controls the secretion of corticotropin-releasing hormone (CRH), corticotropin (adrenocorticotropic hormone, ACTH), and cortisol. Release of CRH from the hypothalamus is influenced by stress, by blood levels of cortisol and by the sleep/wake cycle. The dexamethasone suppression test (DST) is the most frequently used test to assess HPA-system function in psychiatric disorders. Patients who have failed to suppress plasma cortisol secretion, i.e. who escape from the suppressive effect of dexamethasone, have a blunted glucocorticoid receptor response. After corticotropin-releasing hormone (CRH) became available for clinical studies, the DST was combined with CRH administration. The resulting combined dexamethasone suppression-corticotropin-releasing hormone stimulation (DST-CRH) test proved to be more sensitive in detecting HPA system changes than the DST. There is a increasing interest in the use of the DEX-CRH test for psychiatric research. The DEXCRH test has been used to study different psychiatric conditions. Major depression, posttraumatic stress disorder (PTSD), alcoholism, and suicidal behavior are major public health problems around the world. Considerable evidence suggests that HPA dysregulation is involved in the pathogenesis of depressive disorders, alcoholism, PTSD, and suicidal behavior. Over the past two decades, there has been a shift from viewing excessive HPA activity in depression as an epiphenomenon to its having specific effects on symptom formation and cognition. The study of HPA function in depression, alcoholism, PTSD, and suicidal behavior may yield new understanding of the pathophysiolgy of these conditions and suggest new approaches for therapeutic interventions. The combined DEX-CRH test may become a useful neuroendocrinological tool for evaluating psychiatric patients.

Original languageEnglish
Title of host publicationExploring the Phenomenon of Suicide
PublisherNova Science Publishers, Inc.
Pages361-372
Number of pages12
ISBN (Print)9781613249246
StatePublished - 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in psychiatric disorders and suicidal behavior'. Together they form a unique fingerprint.

Cite this